Trial Profile

Multicentre, International Neoadjuvant Randomized Double-blind Trial Comparing Fulvestrant to a Combination of Fulvestrant and Palbociclib (CDK 4/6 Inhibitor) in Patients With Operable Luminal Breast Cancer Responding to Fulvestrant

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 11 Aug 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

01 Aug 2023 Results assessing efficacy of neoadjuvant palbociclib in advanced breast cancer patients were published in the Journal of Cancer Research and Clinical Oncology
03 Aug 2022 Status changed from active, no longer recruiting to completed.
07 Jun 2022 Status changed from recruiting to active, no longer recruiting as per results presented at the 58th Annual Meeting of the American Society of Clinical Oncology

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com